Francisco Fermin Castro Navas

Francisco Fermin Castro Navas

Auto-generated profile, based on publicly available information

Francisco Fermin Castro Navas

Dipartimento di Scienze Farmaceutiche, Università degli studi di Perugia, via del Liceo 1, 06123, Perugia, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Maura MarinozziMaura Marinozzi
Maura Marinozzi
FNFrancisco Fermin Castro Navas
Francisco Fermin Castro Navas
DMDaniela Maggioni
Daniela Maggioni
ECEmanuele Carosati
Emanuele Carosati
GBGiovanni Bocci
Giovanni Bocci
VRVincenzo Russo
Vincenzo Russo
A series of stigmasterol and ergosterol derivatives, characterized by the presence of oxygenated functions at C-22 and/or C-23 positions, were designed as potential liver X receptor (LXR) agonists. The absolute configuration of the newly created chiral centers was definitively assigned for all the corresponding compounds. Among the 16 synthesized compounds, 21, 27, and 28 were found to be selective LXRα agonists, whereas 20, 22, and 25 showed good selectivity for the LXRβ isoform. In particular, 25 showed the same degree of potency as 22R-HC (3) at LXRβ, while it was virtually inactive at LXRα (EC50 = 14.51 μM). Interestingly, 13, 19, 20, and 25 showed to be LXR target gene-selective modulators, by strongly inducing the expression of ABCA1, while poorly or not activating the lipogenic genes SREBP1 and SCD1 or FASN, respectively.

1 May 2018 in Chemistry and Physics of Lipids
Verified
Journal Article
Closed access
FNFrancisco Fermin Castro Navas
Francisco Fermin Castro Navas
GGGianluca Giorgi
Gianluca Giorgi
DMDaniela Maggioni
Daniela Maggioni
MPManuela Pacciarini
Manuela Pacciarini
VRVincenzo Russo
Vincenzo Russo
Maura MarinozziMaura Marinozzi
Maura Marinozzi

1 March 2015 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
FCFrancisco Fermín Castro-Navas
Francisco Fermín Castro-Navas
SSSantiago Schiaffino-Ortega
Santiago Schiaffino-Ortega
MCMaría Carrasco-Jiménez
María Carrasco-Jiménez
PRPablo Ríos-Marco
Pablo Ríos-Marco
CMCarmen Marco
Carmen Marco
Luisa Carlota Lopez CaraLuisa Carlota Lopez Cara
Luisa Carlota Lopez Cara
Aim: Research of the antitumor properties of biscationic compounds has received significant attention over the last few years. Results: A novel family of 1,1′-([2,2′-bipyridine]-5,5′-diylbis(methylene))bis-substituted bromide (9a-k), containing two nitrogen atoms in the linker, considered as hypothetical hydrogen bond acceptors, were synthesized and evaluated as ChoK inhibitors and their antiproliferative activity against six cancer cell lines. Conclusion: The most promising compounds in this series are 1,1′-([2,2′-bipyridine]-5,5′-diylbis(methylene))bis(4-(methyl(phenyl)amino)-quinolinium bromide derivatives 9g-i (analogs to RSM932A), that significantly inhibit cancer cell growth at even submicromolar concentrations, especially against leukemia cells. Compounds 9g-i also inhibit the ChoKα1 with good or moderate values, as predicted by initial docking studies. In addition, the most active compound 9h remarkably induces apoptosis in two cell lines following the mitochondrial pathway.